argenx SE (NASDAQ: ARGX) Stock Competitors & Peer Comparison

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while VRTX trades at $477.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas VRTX's P/E ratio is 25.35. In terms of profitability, ARGX's ROE is +0.32%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, ARGX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check VRTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while REGN trades at $762.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas REGN's P/E ratio is 16.71. In terms of profitability, ARGX's ROE is +0.32%, compared to REGN's ROE of +0.18%. Regarding short-term risk, ARGX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check REGN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARGX's ROE is +0.32%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ARGX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check VRNA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARGX's ROE is +0.32%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARGX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check SGEN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RVMDW trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, ARGX's ROE is +0.32%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, ARGX is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RVMDW's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RVMD trades at $187.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RVMD's P/E ratio is -26.52. In terms of profitability, ARGX's ROE is +0.32%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, ARGX is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RVMD's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ONC trades at $316.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ONC's P/E ratio is 70.70. In terms of profitability, ARGX's ROE is +0.32%, compared to ONC's ROE of +0.12%. Regarding short-term risk, ARGX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ONC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ALNY trades at $205.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ALNY's P/E ratio is 37.02. In terms of profitability, ARGX's ROE is +0.32%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ARGX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ALNY's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ROIV trades at $33.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ROIV's P/E ratio is -34.86. In terms of profitability, ARGX's ROE is +0.32%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, ARGX is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ROIV's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while INCY trades at $119.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas INCY's P/E ratio is 16.06. In terms of profitability, ARGX's ROE is +0.32%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ARGX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INCY's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while BNTX trades at $90.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas BNTX's P/E ratio is -19.61. In terms of profitability, ARGX's ROE is +0.32%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, ARGX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BNTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while UTHR trades at $517.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas UTHR's P/E ratio is 19.10. In terms of profitability, ARGX's ROE is +0.32%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ARGX is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check UTHR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MRNA trades at $54.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MRNA's P/E ratio is -6.73. In terms of profitability, ARGX's ROE is +0.32%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MRNA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while INSM trades at $98.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas INSM's P/E ratio is -17.15. In terms of profitability, ARGX's ROE is +0.32%, compared to INSM's ROE of -1.30%. Regarding short-term risk, ARGX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INSM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARGX's ROE is +0.32%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, ARGX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BGNE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.32%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ARGX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNA-WT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while GMAB trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas GMAB's P/E ratio is 20.77. In terms of profitability, ARGX's ROE is +0.32%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, ARGX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check GMAB's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while NBIX trades at $166.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas NBIX's P/E ratio is 24.10. In terms of profitability, ARGX's ROE is +0.32%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ARGX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check NBIX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while JAZZ trades at $252.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, ARGX's ROE is +0.32%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, ARGX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check JAZZ's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while BBIO trades at $80.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas BBIO's P/E ratio is -21.41. In terms of profitability, ARGX's ROE is +0.32%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, ARGX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BBIO's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ASND trades at $243.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ASND's P/E ratio is -100.79. In terms of profitability, ARGX's ROE is +0.32%, compared to ASND's ROE of -56.42%. Regarding short-term risk, ARGX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ASND's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while EXEL trades at $53.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas EXEL's P/E ratio is 15.88. In terms of profitability, ARGX's ROE is +0.32%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, ARGX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EXEL's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARGX's ROE is +0.32%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARGX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check KRTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ARWR trades at $84.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ARWR's P/E ratio is -39.37. In terms of profitability, ARGX's ROE is +0.32%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, ARGX is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ARWR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while BMRN trades at $60.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas BMRN's P/E ratio is 28.86. In terms of profitability, ARGX's ROE is +0.32%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, ARGX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BMRN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while TECH trades at $72.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas TECH's P/E ratio is 37.16. In terms of profitability, ARGX's ROE is +0.32%, compared to TECH's ROE of +0.05%. Regarding short-term risk, ARGX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TECH's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARGX's ROE is +0.32%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ARGX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RNAM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while AXSM trades at $217.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas AXSM's P/E ratio is -56.92. In terms of profitability, ARGX's ROE is +0.32%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, ARGX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check AXSM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MDGL trades at $467.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MDGL's P/E ratio is -36.51. In terms of profitability, ARGX's ROE is +0.32%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ARGX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MDGL's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while SMMT trades at $13.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas SMMT's P/E ratio is -8.14. In terms of profitability, ARGX's ROE is +0.32%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ARGX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SMMT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while KRYS trades at $341.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas KRYS's P/E ratio is 45.60. In terms of profitability, ARGX's ROE is +0.32%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KRYS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while HALO trades at $82.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas HALO's P/E ratio is 17.87. In terms of profitability, ARGX's ROE is +0.32%, compared to HALO's ROE of +1.26%. Regarding short-term risk, ARGX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check HALO's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CYTK trades at $77.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CYTK's P/E ratio is -13.23. In terms of profitability, ARGX's ROE is +0.32%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, ARGX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CYTK's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARGX's ROE is +0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RXDX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ABVX trades at $124.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ABVX's P/E ratio is -65.48. In terms of profitability, ARGX's ROE is +0.32%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ARGX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ABVX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARGX's ROE is +0.32%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARGX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check NUVL's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CRNX trades at $83.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CRNX's P/E ratio is -16.28. In terms of profitability, ARGX's ROE is +0.32%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARGX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CRNX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while PTGX trades at $136.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas PTGX's P/E ratio is -75.49. In terms of profitability, ARGX's ROE is +0.32%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, ARGX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTGX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARGX's ROE is +0.32%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARGX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check IMGN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while IONS trades at $51.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas IONS's P/E ratio is -30.10. In terms of profitability, ARGX's ROE is +0.32%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IONS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while PRAX trades at $307.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas PRAX's P/E ratio is -23.02. In terms of profitability, ARGX's ROE is +0.32%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, ARGX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRAX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while SYRE trades at $98.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas SYRE's P/E ratio is -47.27. In terms of profitability, ARGX's ROE is +0.32%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, ARGX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SYRE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while KYMR trades at $103.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas KYMR's P/E ratio is -29.29. In terms of profitability, ARGX's ROE is +0.32%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, ARGX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KYMR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ALKS trades at $48.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ALKS's P/E ratio is 52.66. In terms of profitability, ARGX's ROE is +0.32%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ARGX is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ALKS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARGX's ROE is +0.32%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BPMC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while APGE trades at $134.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas APGE's P/E ratio is -30.97. In terms of profitability, ARGX's ROE is +0.32%, compared to APGE's ROE of -0.33%. Regarding short-term risk, ARGX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APGE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARGX's ROE is +0.32%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARGX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CERE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while TGTX trades at $52.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas TGTX's P/E ratio is 17.88. In terms of profitability, ARGX's ROE is +0.32%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, ARGX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TGTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while IMVT trades at $38.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas IMVT's P/E ratio is -14.46. In terms of profitability, ARGX's ROE is +0.32%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, ARGX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IMVT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while PCVX trades at $54.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas PCVX's P/E ratio is -7.86. In terms of profitability, ARGX's ROE is +0.32%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PCVX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while IBRX trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas IBRX's P/E ratio is -8.44. In terms of profitability, ARGX's ROE is +0.32%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, ARGX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IBRX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARGX's ROE is +0.32%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ARGX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MTSR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARGX's ROE is +0.32%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ARGX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRUS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RYTM trades at $99.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RYTM's P/E ratio is -31.71. In terms of profitability, ARGX's ROE is +0.32%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, ARGX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RYTM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARGX's ROE is +0.32%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ARGX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ACLX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while COGT trades at $38.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas COGT's P/E ratio is -18.45. In terms of profitability, ARGX's ROE is +0.32%, compared to COGT's ROE of -0.83%. Regarding short-term risk, ARGX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check COGT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARGX's ROE is +0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARGX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RETA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MIRM trades at $105.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MIRM's P/E ratio is -7.78. In terms of profitability, ARGX's ROE is +0.32%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, ARGX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MIRM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while BLTE trades at $158.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas BLTE's P/E ratio is -84.82. In terms of profitability, ARGX's ROE is +0.32%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, ARGX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BLTE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ERAS trades at $18.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ERAS's P/E ratio is -19.51. In terms of profitability, ARGX's ROE is +0.32%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, ARGX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ERAS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CGON trades at $71.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CGON's P/E ratio is -30.55. In terms of profitability, ARGX's ROE is +0.32%, compared to CGON's ROE of -0.23%. Regarding short-term risk, ARGX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CGON's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARGX's ROE is +0.32%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARGX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CNTA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while XENE trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas XENE's P/E ratio is -13.33. In terms of profitability, ARGX's ROE is +0.32%, compared to XENE's ROE of -0.49%. Regarding short-term risk, ARGX is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check XENE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while LGND trades at $287.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas LGND's P/E ratio is 34.48. In terms of profitability, ARGX's ROE is +0.32%, compared to LGND's ROE of +0.16%. Regarding short-term risk, ARGX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check LGND's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while SRRK trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas SRRK's P/E ratio is -13.17. In terms of profitability, ARGX's ROE is +0.32%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, ARGX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SRRK's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while PTCT trades at $68.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas PTCT's P/E ratio is -29.19. In terms of profitability, ARGX's ROE is +0.32%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ARGX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTCT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARGX's ROE is +0.32%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ARGX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CDTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARGX's ROE is +0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARGX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ABCM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARGX's ROE is +0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARGX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ISEE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARGX's ROE is +0.32%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARGX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APLS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while TVTX trades at $55.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas TVTX's P/E ratio is -254.05. In terms of profitability, ARGX's ROE is +0.32%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, ARGX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TVTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARGX's ROE is +0.32%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ARGX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TERN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while DFTX trades at $43.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.32%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, ARGX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DFTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while DYN trades at $25.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas DYN's P/E ratio is -7.82. In terms of profitability, ARGX's ROE is +0.32%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ARGX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DYN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CRSP trades at $47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CRSP's P/E ratio is -9.39. In terms of profitability, ARGX's ROE is +0.32%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, ARGX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CRSP's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARGX's ROE is +0.32%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ARGX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check FOLD's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARGX's ROE is +0.32%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ARGX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check AKRO's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while DNTH trades at $106.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas DNTH's P/E ratio is -25.89. In terms of profitability, ARGX's ROE is +0.32%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, ARGX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNTH's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARGX's ROE is +0.32%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARGX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ALPN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ACAD trades at $25.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ACAD's P/E ratio is 12.68. In terms of profitability, ARGX's ROE is +0.32%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, ARGX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ACAD's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CAI trades at $15.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CAI's P/E ratio is -86.19. In terms of profitability, ARGX's ROE is +0.32%, compared to CAI's ROE of +0.06%. Regarding short-term risk, ARGX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CAI's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MANE trades at $105.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MANE's P/E ratio is -33.36. In terms of profitability, ARGX's ROE is +0.32%, compared to MANE's ROE of -0.84%. Regarding short-term risk, ARGX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MANE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARGX's ROE is +0.32%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARGX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check OPT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARGX's ROE is +0.32%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARGX is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check PRTC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CELC trades at $86.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CELC's P/E ratio is -22.15. In terms of profitability, ARGX's ROE is +0.32%, compared to CELC's ROE of -2.45%. Regarding short-term risk, ARGX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CELC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while EWTX trades at $38.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas EWTX's P/E ratio is -23.15. In terms of profitability, ARGX's ROE is +0.32%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EWTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARGX's ROE is +0.32%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARGX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ELVN trades at $54.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ELVN's P/E ratio is -32.82. In terms of profitability, ARGX's ROE is +0.32%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, ARGX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ELVN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ARGX's ROE is +0.32%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARGX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CPRX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARGX's ROE is +0.32%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARGX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RYZB's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARGX's ROE is +0.32%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARGX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CBAY's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while VKTX trades at $31.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas VKTX's P/E ratio is -7.67. In terms of profitability, ARGX's ROE is +0.32%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ARGX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check VKTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while DNLI trades at $23.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas DNLI's P/E ratio is -7.99. In terms of profitability, ARGX's ROE is +0.32%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, ARGX is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNLI's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ORKA trades at $96.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ORKA's P/E ratio is -49.75. In terms of profitability, ARGX's ROE is +0.32%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, ARGX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ORKA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ADPT trades at $22.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ADPT's P/E ratio is -41.80. In terms of profitability, ARGX's ROE is +0.32%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, ARGX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ADPT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ALMS trades at $28.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ALMS's P/E ratio is -7.39. In terms of profitability, ARGX's ROE is +0.32%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, ARGX is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ALMS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while RCUS trades at $28.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas RCUS's P/E ratio is -8.66. In terms of profitability, ARGX's ROE is +0.32%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, ARGX is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RCUS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ARGX's ROE is +0.32%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ARGX is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check SWTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 54.3B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, ARGX is priced at $853.82 on the NASDAQ, while ARQT trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 78.75, whereas ARQT's P/E ratio is -933.00. In terms of profitability, ARGX's ROE is +0.32%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, ARGX is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ARQT's competition here